Novo Nordisk A/S (NVO) Q2 2025 Earnings Call Transcript
Novo Nordisk A/S (NVO) Q2 2025 Earnings Conference Call August 6, 2025 7:00 AM ET Company Participants David S. Moore - Executive VP of US Operations & Member of Management Board Jacob Martin Wiborg Rode - Head of Investor Relations Karsten Munk Knudsen - Executive VP, CFO & Member of the Management Board Lars Fruergaard Jorgensen - President, CEO & Member of Management Board Ludovic Helfgott - Executive VP of Product & Portfolio Strategy and Member of Management Board Martin Holst Lange - Executive VP of Development & Member of the Management Board Maziar Mike Doustdar - Executive VP of International Operations & Member of the Management Board Conference Call Participants Emmanuel Douglas Papadakis - Deutsche Bank AG, Research Division Evan David Seigerman - BMO Capital Markets Equity Research Martin Parkhoi - SEB, Research Division Michael Novod - Nordea Markets, Research Division Michael Thomas Nedelcovych - TD Cowen, Research Division Peter Verdult - BNP Paribas Exane, Research Division Richard Vosser - JPMorgan Chase & Co, Research Division Sachin Jain - BofA Securities, Research Division Operator Good day, and thank you for standing by.
Novo Nordisk: Is there life after slow death for slimmed down drug maker?
After a brutal 52% slide this year (not helped by a surprise profit warning last week), Novo Nordisk (NYSE:NVO) is struggling to regain its footing. Wednesday's second-quarter results confirmed the picture: rising competition in the weight-loss market is hitting margins, with Eli Lilly's Mounjaro and cheaper compounded copycats in the US putting the squeeze on Wegovy and Ozempic sales.
Novo Norisk: The struggle is real and getting harder by the day
After last week's profit warning and leadership shake-up, Novo Nordisk's latest earnings update offered little new, though the company's growing struggle against rivals such as Eli Lilly and cheaper weight-loss drug alternatives in the US continues to loom large. The Danish group, known for its blockbuster obesity treatment Wegovy, confirmed it would tighten its commercial operations and rein in spending following a turbulent week that saw it slash its 2025 outlook and announce a change at the top.
Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues
Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded versions of the drug.
Wegovy maker Novo Nordisk's sales hike in second quarter
Wegovy maker Novo Nordisk's sales hike in second quarter
Novo Nordisk's weight loss challenge in five charts
Danish drugmaker Novo Nordisk is facing a major challenge to its blockbuster weight-loss drug Wegovy.
Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now.
The drugmaker is slated to report its second-quarter financial results early Wednesday.
Nordisk to downgraded by leading investment bank as growth slows and competition intensifies
UBS has lowered its rating on Novo Nordisk (NYSE:NVO) from 'buy' to 'neutral', slashing the price target to DKK340 from DKK600. The downgrade comes after what UBS described as “challenging times” for the Danish pharmaceutical group, citing a sharp slowdown in growth for its flagship GLP-1 medicines, intensifying competition from Eli Lilly, and persistent pricing pressures.
Novo Nordisk Stock Sinks—But Is a Bottom Finally In?
Novo Nordisk A/V NYSE: NVO stock is testing the patience of buy-and-hold investors. Over the last five years, NVO stock is up more than 200%.
Watch These Novo Nordisk Stock Price Levels After Last Week's 33% Drop
Novo Nordisk's (NVO) U.S.-listed shares were up about 2% in recent trading after shedding about a third of their value last week, when the company cut its full-year outlook and named a new CEO, leading Wall Street analysts to downgrade the stock.
Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?
NVO's second-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, Wegovy, Ozempic and Rybelsus.
Novo Nordisk: I Was Wrong Twice, But This Selloff Looks Like 2016 All Over Again
I'm downgrading Novo Nordisk from Strong Buy to Buy due to recent guidance cuts, competitive pressures, and persistent compounded GLP-1 drug erosion. The long-term obesity drug opportunity, Novo's manufacturing scale, and a strong pipeline still support a bullish multi-year thesis. Novo is attractively valued after the sell-off, but near-term recovery requires patience; it's a Buy for long-term investors comfortable with volatility.
